Initial SARS-CoV-2 research and the COVID antibody trial in London, conducted by the Andrew Shaw Research Group on the Attomarker platform, would not have been possible without the generous support of over 1,000 donors to the University of Exeter Emergency Appeal launched at the start of the pandemic.
